Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of ARQ-154 Foam in Seborrheic Dermatitis
NCT04445987Phase 2Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast in seborrheic dermatitis (SD), sponsored by Arcutis Biotherapeutics. Started Jun 2020; status: completed.
02
Drugs
roflumilast
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT04445987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445987.